Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Revenue	$ 76	$ 200	$ 265	$ 200
Operating expenses:
Cost of revenue	1,626	144	1,996	144
Sales and marketing	4,736	2,293	13,559	5,555
General and administrative	10,320	6,109	30,982	16,314
Amortization of acquired intangible assets	505	17	1,278	23
Research and development	6,202	5,305	18,873	12,878
Total operating expenses	23,389	13,868	66,688	34,914
Net loss from operations	(23,313)	(13,668)	(66,423)	(34,714)
Other income (expense):
Interest expense	(525)		(1,049)
Change in fair value - Senior Secured Convertible Notes and Senior Convertible Note	261		(1,739)	1,682
Loss on issue and offering costs - Senior Secured Convertible Note	(1,232)		(4,332)
Debt extinguishments loss - Senior Secured Convertible Notes	(5,123)		(5,123)	(3,715)
Debt forgiveness				300
Other income (expense), net	(6,619)		(12,243)	(1,733)
Loss before provision for income tax	(29,932)	(13,668)	(78,666)	(36,447)
Provision for income taxes
Net loss before noncontrolling interests	(29,932)	(13,668)	(78,666)	(36,447)
Net loss attributable to the noncontrolling interests	3,806	1,441	10,143	3,318
Net loss attributable to PAVmed Inc.	(26,126)	(12,227)	(68,523)	(33,129)
Less: Series B Convertible Preferred Stock dividends earned	(71)	(67)	(209)	(216)
Net loss attributable to PAVmed Inc. common stockholders	$ (26,197)	$ (12,294)	$ (68,732)	$ (33,345)
Per share information:
Net loss per share attributable to PAVmed Inc. - basic and diluted	$ (0.29)	$ (0.15)	$ (0.78)	$ (0.41)
Net loss per share attributable to PAVmed Inc. common stockholders – basic and diluted	$ (0.29)	$ (0.15)	$ (0.78)	$ (0.42)
Weighted average common shares outstanding, basic and diluted	89,758,927	83,307,170	87,724,124	79,873,583